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Abstract
Background: Healthcare-associated pneumonia (HCAP) has more similarities to nosocomial pneumonia than to
community-acquired pneumonia (CAP). However, there have only been a few epidemiological studies of HCAP in
South Korea. We aimed to determine the differences between HCAP and CAP in terms of clinical features,
pathogens, and outcomes, and to clarify approaches for initial antibiotic management.
Methods: We conducted a retrospective, observational study of 527 patients with HCAP or CAP who were
hospitalized at Severance Hospital in South Korea between January and December 2008.
Results: Of these patients, 231 (43.8%) had HCAP, and 296 (56.2%) had CAP. Potentially drug-resistant (PDR)
bacteria were more frequently isolated in HCAP than CAP (12.6% vs. 4.7%; P = 0.001), especially in the low-risk
group of the PSI classes (41.2% vs. 13.9%; P = 0.027). In-hospital mortality was higher for HCAP than CAP patients
(28.1% vs. 10.8%, P < 0.001), especially in the low-risk group of PSI classes (16.4% vs. 3.1%; P = 0.001). Moreover,
tube feeding and prior hospitalization with antibiotic treatment within 90 days of pneumonia onset were
significant risk factors for PDR pathogens, with odds ratios of 14.94 (95% CI 4.62-48.31; P < 0.001) and 2.68 (95% CI
1.32-5.46; P = 0.007), respectively.
Conclusions: For HCAP patients with different backgrounds, various pathogens and antibiotic resistance of should
be considered, and careful selection of patients requiring broad-spectrum antibiotics is important when physicians
start initial antibiotic treatments.
Background
Pneumonia has traditionally been classified as either
community- or hospital- acquired, based on the patient’s
location when the infection was acquired. However, an
increasing number of out-of-hospital services, such as
nursing homes, outpatient parenteral therapy, hemodia-
lysis clinics, and domiciliary care, create a class of
patients who do not truly reside in the “community.”
Previous studies have suggested that nursing home-
acquired pneumonia or pneumonia in long-term care
facilities should be considered separately from commu-
nity-acquired pneumonia (CAP) [1-3]. Infections occur-
ring in these patients show a more similar epidemiological
pattern to hospital-acquired pneumonia (HAP) than to
CAP [1-3]. Different epidemiological patterns from CAP
require a distinct targeted therapeutic approach, especially
against multidrug-resistant pathogens [4,5]. Thus, since
2000, the newly published CAP guidelines have recom-
mended management specific to this type of pneumonia,
and considered it to be a separate entity from CAP [6-8].
In 2005, the American Thoracic Society (ATS)/Infec-
tious Diseases Society of America (IDSA) documented
healthcare-associated pneumonia (HCAP) as a new cate-
gory of pneumonia [9]. However, only a few studies on
HCAP have included patients who met the criteria of
the 2005 ATS/IDSA guidelines [10]. Previous HCAP
studies have revealed a diverse composition of partici-
pants because this new HCAP category includes various
criteria for heterogeneous conditions, such as nursing
home residence, previous antibiotic therapy, or regular
attendance at a dialysis clinic [11-13]. Since the criteria
for defining HCAP have not been standardized between
these studies, and due to the existence of geographically
different etiologies, more data are required for a better
characterization of unified HCAP and for redefining
HCAP.
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In South Korea, there are limited data and no thera-
peutic guidelines focusing on HCAP [14]. Considering
the relatively small proportion of long-term care facil-
ities and the different antibiotic resistance patterns of
the microorganisms in CAP, the clinical composition,
causative pathogens, and clinical outcomes of HCAP in
South Korea could be different from those in other
countries. Therefore, a study evaluating HCAP charac-
teristics and clinical outcomes in South Korea is needed.
The aim of this study was to categorize patients
according to the 2005 ATS/IDSA guidelines, to deter-
mine differences in baseline characteristics, pathogens,
and clinical outcomes between patients with HCAP
and CAP in a university teaching hospital in South
Korea, and to clarify approaches for initial antibiotic
management.
Methods
Study design and subjects
We conducted a retrospective observational study of 527
patients with CAP or HCAP who were hospitalized at
Severance Hospital (a 2,000-bed university tertiary refer-
ral hospital in Seoul, South Korea) between January 1
and December 31, 2008. Patients were classified into
either a CAP or HCAP group, according to the 2005
ATS/IDSA guidelines. We compared baseline character-
istics, and identified pathogens, antibiotics regimens,
and clinical outcomes between the two groups. The
study protocol was approved by the Ethical Review
Committee of Severance Hospital.
Definitions
Pneumonia was defined as the presence of a new infil-
trate on the chest radiography plus at least one of the
following: fever (temperature ≥ 38.0°C) or hypothermia
(temperature < 35.0°C), new cough with or without spu-
tum production, pleuritic chest pain, dyspnea, or altered
breath sounds on auscultation [15].
HCAP included any patient who fulfilled any of the
following: (1) hospitalization in an acute care hospital
for two or more days within 90 days of the infection;
(2) residence in a nursing home or long-term care facil-
ity; (3) infusion therapy, such as intravenous antibiotic
therapy, chemotherapy or wound care, within 30 days of
a current infection; (4) regular attendance at a dialysis
clinic, including hemodialysis and peritoneal dialysis [9].
CAP included any patient with pneumonia who did not
meet the HCAP criteria.
Patients were defined as being immunosuppressed if
they fulfilled at least one of the following criteria:
(1) daily administration of systemic corticosteroids (at least
15 mg of prednisone per day for more than one month or
combination therapy with low dose corticosteroids
and other immunosuppressants including azathioprine,
mycophenolate, methotrexate, cyclosporine, or cyclopho-
sphamide) (2) seropositivity for human immunodeficiency
virus; (3) receipt of either a solid organ or bone marrow
transplant; (4) treatment with radiation therapy or che-
motherapy for an underlying malignancy during the 6
months prior to hospital admission; or (5) underlying
acquired immune deficiency disorder [11,13].
In this study, potentially drug resistant (PDR) patho-
gens included methicillin-resistant Staphylococcus aur-
eus (MRSA), Pseudomonas aeruginosa, Acinetobacter
baumannii, Stenotrophomonas maltophilia, and
extended spectrum b-lactamase (ESBL)-producing Enter-
obacteriaceae, based on previous reports showing pro-
blematic clinical outcomes for infections caused by
these pathogens [16,17].
Inappropriate antibiotic therapy was defined as when
any initially prescribed antibiotics were not active
against the identified pathogens, based on in vitro sus-
ceptibility testing [10,12].
The definition of early treatment failure was clinical
deterioration within 72 hours of starting treatment, such
as a lack of response or worsening of fever, respiratory
condition, and/or radiographic status, requiring mechan-
ical ventilation or aggressive fluid resuscitation or vaso-
pressors, or death [12,18,19].
The severity of pneumonia was evaluated and categor-
ized using the validated prediction rule and pneumonia
severity index (PSI) scores: low, class I to III; intermedi-
ate, class IV; high, class V [20,21].
Antibiotic treatment
Antibiotic therapy was initiated in basic accordance with
the ATS/IDSA guidelines (8,9), but the detailed antibio-
tic regimen complied with the attending physician’s
choice taking into consideration patient risk factors and
the severity of the disease. Empirical antibiotic therapy
was modulated after the pathogen was identified accord-
ing to the susceptibility test. However, the antibiotic
therapy was changed or extended according to the
attending physician’s decision for patients in whom the
pathogen was not identified or whose clinical condition
deteriorated.
Microbiological studies
Pathogens in samples obtained from sputum, blood, or
other samples were investigated using standard micro-
biological procedures. Blood cultures were accepted as
an etiological diagnosis if no other source could be iden-
tified for the positive blood culture. Sputum samples
were cultured in a semi-quantitative manner, and an
etiological diagnosis was established when a predomi-
nant microorganism was isolated from group 4 or 5
sputum, according to Murray and Washington’s grading
system [22]. A rapid immunochromatographic assay was
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used for detecting the Streptococcus pneumoniae antigen
(BinaxNOW® S. pneumoniae Test; Binax Inc., Scarbor-
ough, ME, USA) and Legionella pneumophila serogroup
I antigen (BinaxNOW® Legionella Test; Binax Inc., Scar-
borough, ME, USA) in urine. Antibodies against atypical
pathogens (Mycoplasma pneumoniae) were detected by
microparticle agglutination assay (MAG). Cases that did
not meet any of these criteria were considered to be
pneumonia of unknown etiology. The antibiotic sensitiv-
ity of all isolates was determined using a disc diffusion
method, according to the Clinical and Laboratory Stan-
dards Institute guidelines [23].
Statistical analyses
Categorical variables were analyzed using the c2 test or
Fisher’s exact test, and continuous variables were ana-
lyzed using Student’s t-test or Mann-Whitney U test.
After testing the distribution of continuous variables,
normally distributed variables were presented as mean ±
standard deviation (SD) and non-normally distributed
variables were presented as median (interquartile range,
[IQRs]). Multivariate analysis was performed using a
logistic regression model to estimate risk factors for
occurrence of PDR pathogens, which was presented
with the odds ratio (OR, 95% confidence intervals, CI).
Potential candidate variables were those with P < 0.05 in
univariate analyses, and the multi-collinearity of vari-
ables was checked. All tests were two-sided and a
P-value < 0.05 was deemed to be statistically significant.
SPSS 18.0 (SPSS, Chicago, IL, USA) was used for all sta-
tistical analyses.
Results
Patient characteristics
Of the 527 patients, 231 (43.8%) were classified as
HCAP and 296 (56.2%) as CAP. The baseline and clini-
cal characteristics of the patients with HCAP and CAP
are shown in Table 1. Of the 231 HCAP patients, 170
(73.6%) had been hospitalized for two or more days
within 90 days of pneumonia, 150 (64.9%) received
intravenous antibiotic therapy/chemotherapy/wound
care within 30 days of pneumonia onset, 24 (10.4%)
attended a hemodialysis clinic, and 21 (9.1%) resided in
a nursing home or extended care facility (data not
shown).
Pathogen distribution
Table 2 shows the distribution of causative organisms.
The numbers of sputum samples evaluated for patho-
gens were 203 (87.9%) in HCAP patients and 266
(89.9%) in CAP patients, and those of blood samples
were 230 (99.6%) in HCAP patients and 289 (97.6%) in
CAP patients (data not shown). An etiological diagnosis
was established in 79 HCAP (34.2%) and 83 CAP
patients (29.1%) (P = 0.206). S. pneumoniae was the
most frequently isolated pathogen in CAP patients,
while Klebsiella pneumoniae was most frequently iso-
lated in HCAP patients. More PDR pathogens were
observed in patients with HCAP.
Antibiotic treatment and clinical outcomes
Initial antibiotic treatments and outcomes for patients
with HCAP and CAP are shown in Table 3. Inappropri-
ate antibiotic therapy tended to be administered more
frequently to HCAP patients than CAP patients,
although the difference was not significant. Patients in
both groups received combination therapy more than
monotherapy. The in-hospital mortality and early treat-
ment failure rates were significantly higher in HCAP
patients than CAP patients. Patients with HCAP stayed
in the hospital longer and showed a more frequent need
for mechanical ventilation than patients with CAP.
Occurrence of PDR pathogens and clinical outcomes and
in each severity class assessed by PSI
Table 4 shows the occurrence of PDR pathogens, early
treatment failure, and mortality in each risk class. In
low-risk patients, HCAP showed a higher occurrence of
PDR pathogens (41.2% vs. 13.9%; P = 0.027) and early
treatment failure (16.4% vs. 6.3%; P = 0.024). Moreover,
patients with HCAP showed higher in-hospital mortality
than those with CAP in the low (16.4% vs. 3.1%; P =
0.001) and intermediate (25.2% vs. 14.1%; P = 0.044)
risk classes.
Risk Factors for Occurrence of PDR Pathogens
The multivariate analysis of risk factors for the occur-
rence of PDR pathogens are shown in Table 5. Tube
feeding and previous hospitalization within 90 days of
pneumonia onset were significant risk factors; the corre-
sponding odds ratios were 14.94 and 2.68. Of 162
patients with identified pathogens, 57 patients (35.2%)
had been previously hospitalized within 90 days of infec-
tion. However, when previous hospitalization was classi-
fied into two different risk factors in relation to
antibiotic treatment, 36 patients (63.2%) had previously
been hospitalized with antibiotic treatment and 21
patients (36.8%) had been hospitalized without. The for-
mer was a significant risk factor (odds ratio = 2.45; 95%
CI 1.19-5.02; P = 0.014), but the latter was not (odds
ratio = 1.59; 95% CI 0.54-4.69; P = 0.398) (data not
shown).
Discussion
This study showed that half of the hospitalized patients
with pneumonia in a university tertiary referral hospital
in South Korea were diagnosed with HCAP, and identi-
fied differences in comorbidities, pathogens, initial
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antibiotic regimens, and clinical outcomes between the
HCAP and CAP groups. Moreover, tube feeding and
prior hospitalization with antibiotic treatment within
90 days of pneumonia were found to be significant risk
factors for PDR pathogens.
Patients with HCAP were more frequently classified
into the intermediate- and high-risk classes than
patients with CAP. More PDR pathogens were identi-
fied, more inappropriate antibiotic treatments were
initiated, and clinical outcomes were worse for HCAP
Table 1 Baseline Characteristics of Patients with HCAP and CAPa
Baseline Characteristics HCAP (n = 231) CAP
(n = 296)
P-value
Age (year) 63.5 ± 13.1 65.4 ± 15.7 0.148
Male 162 (70.1) 194 (65.5) 0.264
Female 69 (29.9) 102 (34.5)
Underlying diseases
Diabetes Mellitus 52 (22.5) 59 (19.9) 0.471
Chronic lung diseaseb 22 (9.5) 56 (18.9) 0.003
Central nervous system disorders 26 (11.3) 47 (15.9) 0.127
Renal disease 31 (13.4) 27 (9.1) 0.118
Hypertension 93 (40.3) 125 (42.2) 0.649
Cardiovascular disease 19 (8.2) 62 (20.9) <0.001
Liver disease 12 (5.2) 16 (5.4) 0.915
Rheumatologic disease 9 (3.9) 18 (6.1) 0.259
Malignancy 156 (67.5) 58 (19.6) <0.001
Solid organ malignancy 133 (57.6) 42 (14.2) <0.001
Hematologic malignancy 26 (11.3) 17 (5.7) 0.022
Clinical parameters
Confusion 35 (15.2) 34 (11.5) 0.216
Septic shock at onset 57 (24.7) 46 (15.5) 0.009
PaO2 < 60 mmHg, SpO2 < 90%, or PaO2/FiO2 < 300 79 (34.2) 96 (32.4) 0.669
Pleural effusion 43 (18.6) 49 (16.6) 0.536
Acute renal failure at onset 32 (13.9) 37 (12.5) 0.648
Laboratory findings
pH < 7.35 10 (4.3) 23 (7.8) 0.106
Hematocrit < 30% 87 (37.7) 51 (17.2) <0.001
Glucose > 250 mg/dL 20 (8.7) 21 (7.1) 0.506
Blood urea nitrogen > 30 mg/dL 67 (29.0) 49 (16.6) 0.001
Leukocytes (×103/μl) 12790 ± 13603 13175 ± 7519 0.700
C-reactive protein (mg/dL) 15.4 ± 11.2 13.1 ± 10.0 0.017
Erythrocyte Sedimentation Rate (mm) 83.2 ± 33.8 71.4 ± 35.7 <0.001
Eastern Cooperative Oncology
Group (ECOG)
1.7 ± 0.9 1.2 ± 0.9 <0.001
Prior antibiotics use 97 (42.0) 6 (1.0) <0.001
Immunosuppressedc 142 (61.5) 39 (13.2) <0.001
Pneumonia Severity Index Risk Classes 113.7 ± 32.3 92.2 ± 33.6 <0.001
Low (I-III) 55 (23.8) 159 (53.7)
Intermediate (IV) 115 (49.8) 99 (33.4) <0.001
High (V) 61 (26.4) 38 (12.8)
a Data are presented as numbers (percentages) unless otherwise indicated. Plus-minus values are means ± standard deviation.
b Chronic lung disease includes asthma, COPD, and structural lung diseases, such as bronchiectasis and interstitial lung disease.
c Immunosuppression includes the following: (1) daily administration of systemic corticosteroids (at least 15 mg of prednisone per day for more than one month
or combination therapy with low dose corticosteroids and other immunosuppressants including azathioprine, mycophenolate, methotrexate, cyclosporine, or
cyclophosphamide); (2) seropositivity for human immunodeficiency virus; (3) received either a solid organ transplant or bone marrow transplant; (4) treated with
radiation therapy or chemotherapy for an underlying malignancy during the 6 months prior to hospital admission; (5) an underlying acquired immune deficiency
disorder.
HCAP healthcare-associated pneumonia.
CAP community-acquired pneumonia.
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patients, especially those in the low and intermediate
risk classes. The results of this study were consistent
with those of previous studies reporting distinct clini-
cal characteristics of HCAP and worse outcomes than
CAP [10,12,14,24]. However, the baseline characteris-
tics and the backgrounds of patients with HCAP dif-
fered slightly from previous reports. In this study,
more patients with HCAP had malignancies (67.5%)
and an immunosuppressive condition (61.5%) as
comorbidity than other studies (14.2% to 22.3%)
[12,24]. Furthermore, the HCAP group included a rela-
tively lower proportion of patients residing in nursing
homes or extended care facilities (9.1%) than previous
reports (28.0% to 61.0%)[12,24]. These differences
indicate the heterogeneous aspect of HCAP and the
difficulty of establishing one unified approach for
patients with HCAP [25].
Despite the high rate of anti-pseudomonal therapy in
HCAP patients, a high proportion of inappropriate initial
Table 2 Pathogen Distribution in Patients with HCAP and
CAPa
Microbes HCAP
(n = 231)
CAP
(n = 296)
P-value
Pathogen identified 79 (34.2) 83 (29.1) 0.206
Gram-positive pathogens 34 (14.7) 54 (18.2) 0.282
MRSA 9 (3.9) 6 (2.0)
MSSA 4 (1.7) 9 (3.0)
Streptococcus pneumoniae 11 (4.8) 33 (11.1)
Streptococcus other 4 (1.7) 3 (1.0)
Enterococcus species 0 (0) 1 (0.3)
Others b 6 (2.6) 3 (1.0)
Gram-negative pathogens 46 (19.9) 28 (9.5) 0.001
Pseudomonas aeruginosa 10 (4.3) 5 (1.7)
Escherichia coli 1 (0.4) 0 (0)
Haemophilus influenzae 2 (0.9) 3 (1.0)
Klebsiella pneumoniae 23 (10.0) 13 (4.4)
ESBL producing c 9/23 (39.1) 3/13 (23.1)
Enterobacter species 4 (1.7) 1 (0.3)
Acinetobacter baumannii 1 (0.4) 0 (0)
Stenotrophomonas maltophilia 1 (0.4) 1 (0.3)
Others d 4 (1.7) 5 (1.7)
Anaerobes e 1 (0.4) 0 (0)
Atypical pathogens f 0 (0) 3 (1.0)
Fungal pathogensg 1 (0.4) 1 (0.3)
PDR pathogens 29 (12.6) 14 (4.7) 0.001
a Data are presented as numbers (percentages) unless otherwise indicated.
b Coagulase-negative Staphylococci species.
c Number of patients/total number of patients in whom Klebsiella pneumonia
was identified (percentages).
d Moraxella catarrhalis (1 in HCAP and 3 in CAP), Serratia marcescens (2 in
HCAP and 2 in CAP), Citrobacter freundii (1 in HCAP).
e Bacteroides fragilis.
r Mycoplasma pneumonia (3 in CAP).
g Aspergillus species.
HCAP healthcare-associated pneumonia.
CAP community-acquired pneumonia.
MRSA methicillin-resistant Staphylococcus aureus.
MSSA methicillin-sensitive Staphylococcus aureus.
ESBL extended-spectrum b-lactamase.
PDR potentially drug-resistant.
Table 3 Antibiotic Treatments and Clinical Outcomes in
Patients with HCAP and CAPa
Treatment HCAP
(n = 231)
CAP
(n = 296)
P-value
Inappropriate antibiotic therapyb 27/73
(37.0)
19/78
(24.4)
0.092
Monotherapy 30 (13.0) 53 (17.9) 0.124
Amino-penicillins 3 (1.3) 5 (1.7) -
Cephalosporin 5 (2.2) 8 (2.7) -
Antipseudomonal penicillins 6 (2.6) 6 (2.0) -
Fluroquinolone 13 (5.6) 34 (11.5) -
Carbapenem 3 (1.3) 0 (0) -
Combination therapy 201 (87.0) 243 (82.1) 0.124
b-lactams + fluoroquinolone 4 (1.7) 8 (2.7) -
b-lactams + macrolide 36 (15.6) 112 (37.8) <0.001
b-lactams + clindamycin 10 (4.3) 14 (4.7) -
b-lactams + aminoglycoside 6 (2.6) 1 (0.3) -
Fluoroquinolone +
clindamycin
13 (5.6) 12 (4.1) -
Antipseudomonal b-lactams +
fluroquinolone
63 (27.3) 48 (16.2) 0.001
Antipseudomonal b-lactams +
macrolide
0 (0) 1 (0.3) -
Antipseudomonal b-lactams +
clindamycin
6 (2.6) 3 (1.0) -
Antipseudomonal b-lactams +
aminoglycoside
8 (3.5) 2 (0.7) -
Other combination therapyc 55 (23.8) 42 (14.2) 0.002
Clinical outcomes
In-hospital mortality 65 (28.1) 32 (10.8) <0.001
Early treatment failured 56 (24.2) 37 (12.5) <0.001
ICU admission 49 (21.2) 37 (12.5) 0.007
ICU mortality 31 (13.4) 21 (7.1) 0.016
Need for mechanical
ventilation
47 (20.3) 39 (13.2) 0.027
Duration of hospital stay (days) 18.6 ± 19.1 12.9 ± 13.1 <0.001
a Data are presented as numbers (percentages) unless otherwise indicated.
Plus-minus values are means ± standard deviation.
b Number of patients/total number of patients whose causative pathogens
and antibiotic sensitivity test results are known (percentages). Results of
antibiotics sensitivity test were not available in six patients with HCAP and five
patients with CAP.
c Others contain combination therapy of three or more drugs, including
aminopenicillins, cephalosporin, antipseudomonal penicillin, aminglycoside,
macrolide, clindamycin, fluoroquinolone, glycopeptide, trimethoprim/
sulfamethoxazole, and antifungal agent.
d Early treatment failure was defined as clinical deterioration within 72 h of
treatment such as lack of response or worsening of fever, respiratory
condition, and/or radiographic status requiring mechanical ventilation,
aggressive fluid resuscitation or vasopressors, or death.
HCAP healthcare-associated pneumonia.
CAP community-acquired pneumonia.
ICU intensive care unit.
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antibiotics were given to the patients in this study
(37.0%), as compared with the studies of Shindo et al.
(20.8%), Carratalà et al. (5.6%), and Park et al. (24.6%)
[10,12,14]. This is likely due to the higher rate of PDR
pathogen infection (36.7%), as compared with the afore-
mentioned reports of Shindo et al. (22.1%), Carratalà
et al. (3.5%), and Park et al. (29.3%) in HCAP patients,
and the relatively high proportion of ESBL-producing
Gram-negative pathogens [10,12,14]. In this study, K.
pneumoniae (10.0%) was the most common pathogen in
patients with HCAP, followed by S. aureus (5.6%), S.
pneumoniae (4.8%), and P. aeruginosa (4.3%) in that
order. In addition, the rate of ESBL-producing K. pneu-
moniae was relatively high in our study. This may be
explained by differences in the underlying comorbidities
of HCAP patients and their reasons for being in contact
with the healthcare environment. A large proportion of
patients with malignancies who had been regularly hospi-
talized for anti-cancer chemotherapy and a considerable
proportion of patients with recent antibiotic therapy
(42.0%) could explain an increasing colonization of
ESBL-producing K. pneumoniae. In a report by Park
et al., another study done in a tertiary hospital of South
Korea, K. pneumoniae is also the second most common
pathogen of HCAP and the rate of ESBL-producing
K. pneumoniae comes to 79% in both CAP and HCAP
[14]. Thus, efforts to identify the pathogens and to adjust
empirical antibiotics accordingly, based on microbiologi-
cal data, are more useful than automatic treatment with
anti-pseudomonal broad-spectrum antibiotics.
Negative clinical outcomes, including early treatment
failure and in-hospital mortality were all higher in
HCAP patients than CAP patients. The differences were
significant, especially among the low-risk class, and the
occurrence of PDR pathogens was also more frequently
observed in HCAP patients than in CAP patients among
the low-risk class. These results were similar to the
study of Shindo et al. in Japan, which showed higher
mortality and PDR pathogens occurrence in HCAP
patients than in CAP patients in the moderate severity
class according to the A-DROP (age, dehydration,
respiratory failure, orientation disturbance, and low
blood pressure) scoring system [12]. In patients classi-
fied as high-risk, mortality was not different between
HCAP and CAP patients, probably due to the severity of
the illness itself, regardless of the presence of PDR
pathogens. The poorer outcomes for patients with
HCAP than for those with CAP in the low-risk class
might be explained by the higher rate of early treatment
failure (16.4% vs. 6.3%; P = 0.024), associated with a
higher proportion of PDR pathogen (41.2% vs. 13.9%;
P = 0.027), as shown in Table 4.
Although we could not find a significant difference in
the rate of inappropriate initial antibiotics treatment
between patients with HCAP and CAP, the proportion of
inappropriate antibiotic treatment was significantly higher
in HCAP patients infected with PDR pathogen than in
those without (58.6% vs. 22.7%; P = 0.002) (data not
shown), which is consistent with previous reports [14,26].
Therefore, it is important to identify risk factors for PDR
pathogens in patients with HCAP to decide who should
receive broad-spectrum antibiotics. These efforts would
improve clinical outcomes and prevent the emergence of
multi-drug resistant microorganisms from overuse of
broad-spectrum antibiotics. According to multivariate ana-
lysis, significant risk factors for PDR pathogens included
the use of antibiotics for more than two days during a
Table 4 Occurrence of PDR Pathogens and Clinical
Outcomes and in Each Severity Class Assessed by the
Pneumonia Severity Index in Patients
Pneumonia Severity Index
Classes
HCAP
(n = 231)
CAP
(n = 296)
P-value
PDR pathogensa
Low (I-III) 7/17 (41.2) 5/36 (13.9) 0.027
Intermediate (IV) 14/40 (35.0) 5/29 (17.2) 0.103
High (V) 8/22 (36.4) 4/18 (22.2) 0.332
Early treatment failureb
Low (I-III) 9/55 (16.4) 10/159 (6.3) 0.024
Intermediate (IV) 21/115 (18.3) 18/99 (18.2) 0.988
High (V) 26/61 (42.6) 9/38 (23.7) 0.055
In-hospital mortalityb
Low (I-III) 9/55 (16.4) 5/159 (3.1) 0.001
Intermediate (IV) 29/115 (25.2) 14/99 (14.1) 0.044
High (V) 27/61 (44.3) 13/38 (34.2) 0.322
a Number of patients/total number of patients whose causative pathogens
were identified in each pneumonia severity index class (percentages).
b Data are presented as number of patients/total number of patients in each
pneumonia severity index class (percentages).
HCAP healthcare-associated pneumonia.
CAP community-acquired pneumonia.
PDR potentially drug-resistant.
Table 5 Multivariate Analysis of Risk Factors for
Occurrence of PDR Pathogens
Risk Factors Odds
Ratio
95% CI P-value
Gender, female 1.50 0.75 - 3.01 0.256
Age 1.00 0.98 - 1.02 0.964
Tube feeding 14.94 4.62 - 48.31 <0.001
Residence in a nursing home or
extended care facility
1.90 0.53 - 6.86 0.327
Intravenous chemotherapy within 30 days 0.62 0.22 - 1.77 0.373
Attended a hemodialysis clinic 2.81 0.86 - 9.19 0.087
Hospitalized in an acute care hospital for
two or more days within 90 days of the
infection
2.68 1.32 - 5.46 0.007
PDR potentially drug-resistant.
CI confidential interval.
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prior hospitalization within 90 days of pneumonia onset as
well as tube feeding. Thus, we suggest that physicians con-
sider broad-spectrum antibiotics for treatment of HCAP
patients with these risk factors for PDR pathogens.
HCAP is a newly defined group since 2005 and has
been composed of heterogeneous patients with various
severities of illness and different reasons for contact
with the healthcare environment. Thus, there is little
detailed data on these various HCAP groups, though it
is associated with significant mortality and high health
care costs [27,28]. This study may provide useful gui-
dance in understanding the characteristics of HCAP and
in developing therapeutic approaches for patients with
HCAP in South Korea.
To fully appreciate our results, we should consider
the limitations of the present study. First, this was a
retrospective study in a single institution with a rela-
tively short duration and may not represent South
Korean medical institutions in general. However, this
study shows the general characteristics of pneumonia
patients admitted to tertiary hospitals in South Korea.
Second, the etiology of pneumonia was identified in a
low proportion of patients. Thus, the true incidence
of PDR pathogen and its effects on the clinical out-
comes could have been underestimated. However, 89%
and 99% of the patients were evaluated using their
sputum and blood samples, and our successful patho-
gen identification rate of 30% was not relatively low
compared to the rate of 20-50% from previous pro-
spectively designed studies [10,29,30]. Third, atypical
pathogens could not be fully evaluated due to inade-
quate information in the medical records. Fourth,
prior antibiotic use could not be fully estimated due
to insufficient information from other clinics in the
medical records.
Conclusions
In summary, half of the hospitalized with pneumonia
in a university tertiary referral hospital were diag-
nosed with HCAP. Patients with HCAP showed a
higher occurrence of PDR pathogens, more frequent
early treatment failure, and a higher mortality rate
than patients with CAP, especially in patients with
low-risk class. Those HCAP patients who underwent
tube feeding and those who have been hospitalized
and given antibiotic treatment within the previous
90 days should be mainly considered for broad-spec-
trum antibiotics.
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